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Edited by Pascale CossartAbstract To identify a novel class of antibiotics, we have devel-
oped a high-throughput genetic system for targeting the homodi-
merization (HD system) of histidine kinase (HK), which is
essential for a bacterial signal transduction system (two-compo-
nent system, TCS). By using the HD system, we screened a
chemical library and identiﬁed a compound, I-8-15 (1-dodecyl-
2-isopropylimidazole), that speciﬁcally inhibited the dimerization
of HK encoded by the YycG gene of Staphylococcus aureus and
induced concomitant bacterial cell death. I-8-15 also showed
antibacterial activity against MRSA (methicillin-resistant
S. aureus) and VRE (vancomycin-resistant Enterococcus fae-
calis) with MICs at 25 and 50 lg/ml, respectively.
 2005 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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The bacterial signal transduction system (two-component
system, TCS) composed of histidine kinase (HK) and response
regulators (RR) plays important roles in drug-resistance, path-
ogenesis and bacterial growth. HKs have recently emerged as
compelling targets for antibacterial drug design for several rea-
sons [1–4]. First, histidine phosphorylation in bacteria is dis-
tinct from serine/threonine and tyrosine phosphorylation in
higher eukaryotes as a mode of signal transduction. Accord-
ingly, a selective HK inhibitor is expected to have minimal tox-
icity in mammalian cells. Second, the high degree of structural
homology in the catalytic domain of HKs suggests that multi-
ple HKs could be inhibited within a single bacterium, thus,
reducing the possibility of resistant strains emerging. Finally,
as HKs are found throughout the genomes of Gram-positive
and Gram-negative bacteria, a single HK inhibitor may exhibit
a broad spectrum of activity provided that it can penetrate the
cell envelopes of the target bacteria.
The YycG/YycF TCS is speciﬁc to low G+C Gram-positive
bacteria, and it is highly conserved among this group of bacte-
ria. The role of the YycG/YycF TCS system includes the prop-
er regulation of bacterial cell wall or membrane composition
[5,6], and it has been shown to be essential in Bacillus subtilis,*Corresponding author.
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coccus aureus [7–10]. Notably, a temperature-sensitive mutant
of this system has been shown to be lethal at a non-permissive
temperature, indicating that this pathway provides an excellent
target in designing novel antibiotics.
On the other hand, dimerization of HK is considered an
essential step for autophosphorylation of this enzyme [11,12].
Cytoplasmic or truncated forms of HKs have previously been
studied and shown to dimerize in vitro [13]. Solution state
NMR [14] indeed revealed dimerization for the homodimeric
core domain in Escherichia coli EnvZ HK, which belongs to
the same Pho subfamily of HKs as YycG [15].
In order to develop a high-throughput genetic system for
targeting the homodimerization (HD system) of HK that in-
cludes YycG, we used the pKWY2428 constructed by Novy
[16], which is a homodimerization vector containing the N-
terminal region (NkcI., 1–133 a.a.) of kcI. First of all, we con-
structed a chimeric repressor (NkcI-CYycG) in which NkcI
was fused to the cytoplasmic region of YycG. NkcI-CYycG
formed to repress the tet and lacZ genes expression in E. coli.
However, the screening system with NkcI-CYycG was labori-
ous and lacked reproducibility. Thus, we tried to construct a
high-throughput homodimerization assay system based on
the dimerization properties of the IclR repressor of E. coli
using GFP as the reporter gene.2. Materials and methods
2.1. Strains, plasmids and growth conditions
E. coli JM109 (endA1, recA1, gyrA96, thi, hsdR17(rK,mK+), relA1,
supE44, D(lac-proAB), (F 0, traD36, proAB, lacIqZ DM15), and
BL21(DE3) (F, ompT, hsdSB, [rB,mB], dcm, gal, k(DE3)) were cul-
tured in Luria–Bertani broth (LB) to screen the chemical library and
express N100, N100-zip or N100-CYycG, respectively. When neces-
sary, LB was supplemented with ampicillin (100 lg/ml) or chloram-
phenicol (25 lg/ml).
2.2. Plasmids construction
pGMIiclR was constructed as follows: 99 bp iclR promoter
(AE000475, 4226880-4226978) was ampliﬁed by PCR using a genomic
DNA template from E. coli W3110 and the primers 5 0-CCACGCAA-
CATGAGATCTGTTCAAC-30 and 5 0-GAATGGGTGCATGCAT-
GACAGTCTC-3 0, which contained BglII and EcoT22I sites
(underlined) for cloning. The PCR product was digested with restric-
tion enzymes and then ligated into EcoT22I and BglII sites of pGMI301
[17]. The BglII–BamHI fragment (1260 bp) of pGMIiclR was cloned
into the BglII–BamHI sites of pTrc99A to obtain pF001 (Fig. 1). iclR
(825 bp, AE000475, 4226882-4226058) was ampliﬁed by PCR using
the primers 5 0-CAGAAAAAAGAGGAATTCATGGTCGCACCC-
3 0 and 5 0-CTCTGCCCGCCAGGGTACCTCAGCGCATTC-3 0 andblished by Elsevier B.V. All rights reserved.
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with EcoRI and KpnI, it was ligated into the corresponding sites of
pF001 to obtain pFI001 (Fig. 1). To construct the truncated IclRs con-
taining 117, 100 and 66 amino acid residues from the N-terminus (Fig.
2A),KpnI sites were introduced into the corresponding sites of iclR gene
on pFI001 by using the Quick Change site-directed mutagenesis kit
(Stratagene) and the following primers (KpnI site underlined):
5 0-GCCATATTGACGGTACCGCCAGACTCTTCC-30 and 5 0-GG-
AAGAGTCTGGCGGTACCGTCAATATGGC-30 for pFI004;
5 0-GGGTGAACAATCGCGGTACCATTACGGCTC-3 0 and 5 0-
GAGCCGTAATGGTACCGCGATTGTTCACCC-3 0 for pFI003;
and, 5 0-GAAACCCTGCTGGGTACCCGTGGTTAGCAG-3 0 and
5 0-CTGCTAACCACGGGTACCCAGCAGGGTTTC-3 0 for pFI002.
These were digested with KpnI and ligated by themselves to construct
pFI004, pFI003 and pFI002 (Fig. 1 and Fig. 2A). The DNA fragments
containing the DNA binding domain of kcI (NcI, 2–132 a.a. from N-
terminal) [16], leucine zipper (zip, 33 a.a. sequence) of yeast GCN4
[18,19], dimerization domain of FadR of E. coli (CFad, 83–239 a.a.
from N-terminal) [20], and the cytoplasmic domain of YycG of S.
aureus (CYycG, 204–608 a.a. from N-terminal) [8] were prepared by
PCR using the following primers and templates: 5 0-GAAACAGGG-
TACCAGCACAAAAAAGAAACC-3 0 and 5 0-CCAATTGAGGG-
TACCCGACACCCATCTCTC-3 0 and pKWY2428 (for NcI);
5 0-CCTATCCAGGGTACCAAACAGCTGGAAGAC-3 0, 5 0-CATA-
GGCCAGGTACCCCACGTTCACCCACC-3 0, and pT18-zip (for
zip); 5 0-GAAATGGTACCGAAACACTGGCGCGACTGG-3 0, 5 0-
CGGGGTACCTTATCGCCCCTGAATGGC-3 0, and genomic
DNA from W3110 (for CFad); 5 0-GATTCGGTACCGCGCGAA-
CGATTACCAAAC-30, 5 0-GTCGGTACCTTATTCATCCCAATCA-
CCGTC-3 0, and pYycGSa (for CYycG). After the DNA fragments
containing zip, NcI, CFad and CYycG were digested with KpnI, they
were fused to the KpnI site of pFI003 to construct pFI006, pFI007,
pFI009 and pFI028, where the C-terminal part of IclR was replaced
by zip, NcI, CFad and CYycG, respectively. The IclR, N100,
N100-zip and N100-CYycG regions were ampliﬁed by PCR using
following primers and templates: 5 0-GACCATGGAACATAT-
GGTCGCACCCATTCC-3 0, 5 0-CAGATCCCCGGGTCTCGAGG-
CGCATTCCAC-3 0, and pFI001 (for IclR); 5 0-GACCATGGAACA-
TATGGTCGCACCCATTCC-3 0, 5 0-GTTGAACAGACTCGAGGG-
TACCATTACGC-3 0, and pFI003 (for N100); 5 0-GACCATGGA-
ACATATGGTCGCACCCATTCC-30, 5 0-CAGATCCCCCTCGAGC-Fig. 1. Construction of plasmids for HD system. To construct the truncate
terminal, KpnI sites were introduced into the corresponding sites of iclR gene
pFI028, CYycG.CCACGTTCACCCAC-30, and pFI006 (for N100-zip); 5 0-GAC-
CATGGAACATATGGTCGCACCCATTCC-3 0, 5 0-CCCCGGGT-
CTCGAGTTCATCCCAATCACCG-30, and pFI028 (for N100-
CYycG). After IclR, N100, N100-zip and N100-CYycG fragments
were digested with NdeI and XhoI, they were ligated into the corre-
sponding sites of pET21(a)+ (Novagen) to obtain pETIclR, pETN100,
pETN100-zip and pETN100-CYycG, respectively. After that,
N100-CYycG-Histag regions were ampliﬁed by PCR using the primers
5 0-GGAGATATACATATGGTCGCACCCATTCCC-3 0 and 5 0-GT-
TAGCAGCGAATTCTCAGTGGTGGTGGTG-3 0 along with
pETN100-CYycG as template DNA. After this ampliﬁed DNA was
digested with NdeI and EcoRI, it was ligated into the corresponding
sites of pCold III (Takara) to obtain pCN100-CYycG.
2.3. Library screening
JM109 containing pFI001, PFI002, pFI003, pFI004, pFI006,
pFI007, pFI009 or pFI028 was cultured at 37 C in LB medium
containing ampicillin (LB-amp, 100 lg/ml). After this, 1 ll of this
culture was added to each 96-titer well containing LB-amp medium
(199 ll) in the presence or absence of the drug from the chemical
library. They were grown at 37 C for 20 h, and the ﬂuorescence lev-
els at an excitation of 485 nm and at an emission of 535 nm, with
optical density at 600 nm (OD600), were measured with Wallac
1420 ARVOsx (Perkin–Elmer Life Science) and Model 3550
Microplate Reader (Bio-Rad) instruments, respectively. The ﬂuores-
cent intensity of each sample was divided by its OD600 value for
normalization.
2.4. Puriﬁcation of CYycG, IclR, N100, N100-zip and N100-CYycG
CYycG from S. aureus was puriﬁed as His6-tag as described previ-
ously [8]. IclR, N100 and N100-zip were also puriﬁed as His6-tag
proteins using BL21 (DE3) containing pETIclR, pETN100 and
pETN100-zip; however, it was diﬃcult to purify N100-CYycG using
pETN100-CYycG because it formed an inclusion body. To purify
N100-CYycG, BL21 (DE3) containing both pCN100-CYycG and
the chaperone plasmid pG-Tf2 (Takara) was cultured at 37 C in an
LB medium (ampicillin, 100 lg/ml; chloramphenicol, 25 lg/ml). After
it was grown to an OD600 of 0.5 at 37 C, it was cultured at 15 C
for 24 h in the presence of IPTG (1 mM) and tetracycline (5 ng/ml)
to purify N100-CYycG as a His6-tag protein.s IclRs containing 117, 100 and 66 amino acid residues from the N-
(step 2). HD, homodimerization domain; pFI006, zip; pFI007, CFad;
Fig. 2. Construction of IclR derivatives and their repressor activities. (A) Construction of E. coli IclR derivatives. Full length of IclR contains 274
amino acid residues. N66, N100 and N117 lack the C-terminal portions of IclR. N100 was fused to NcI, zip, CFad, or CYycG. (B) Fluorescent
intensity of IclR and chimeric repressors. E. coli JM109 containing pFI001 (lane 1), pFI004 (lane 2), pFI003 (lane 3), pFI002 (lane 4), pFI007 (lane 5),
pFI006 (lane 6), pFI009 (lane 7), or pFI028 (lane 8) was cultured and their ﬂuorescent intensity was measured as described in Section 2. Each
intensity was represented as relative value to that of JM109/pFI001.
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IclR, N100, N100-zip or N100-CYycG (100 pmol) was incubated in
100 ll of HMKG buﬀer (50 mM HEPES [pH 7.5], 10 mM MgCl2,
50 mM KCl, 20% glycerol) containing 300 lM imidazole for 30 min
on ice. When necessary, dimethyl sulfoxide (DMSO) or I-8-15 was
added and incubated for 15 min at room temperature. 0.3 mM disuc-
cinimidyl suberate (DSS) was added to react with two side chains of
protein targets to form a cross-linked complex [21]. After 2 h of incu-
bation at room temperature, the reactions were stopped by the addi-
tion of 0.25 M glycine and trichloroacetic acid (TCA). The proteins
were run on sodium dodecyl sulphate–polyacrylamide gel electropho-
resis (SDS–PAGE). The gels were electrotransferred onto polyvinyli-
dene diﬂuoride membranes (PVDF) that were then probed with
polyclonal antibodies against IclR. The primary antibody was detected
with a goat anti-rabbit IgG (H+L) alkaline phosphatase conjugated
detection system (Bio-Rad).2.6. Gel mobility shift assay
The 32P-labeled probe was generated by PCR ampliﬁcation using a
primer pair for the iclR promoter (5 0-CCACGCAACATGA-
GATCTGTTCAAC-30 and 5 0-GAATGGGTGCATGCATGA-
CAGTCTC-3 0). The forward primer was labeled with 10 lCi of
[c-32P]ATP (5000 Ci/mmol) by T4 polynucleotide kinase (Toyobo).
E. coli W3110 genome DNA (100 ng) was used as the template for
Ex Taq DNA polymerase (Takara). The PCR product with 32P at its
terminus was recovered from a polyacrylamide gel, and then a gel
mobility shift assay was done. The 32P-labeled probe (5000 cpm) was
incubated with puriﬁed IclR, N100, N100-zip, N100-CYycG or bovine
serum albumin (BSA) proteins for 20 min at 37 C in 12.5 ll of binding
buﬀer [10 mM Tris–HCl (pH 7.4), 3 mM MgCl2, 5 mM CaCl2, 1 mM
EDTA, 50 mMKCl, 5% glycerol, 0.05% Nonidet P-40]. After adding a
DNA dye solution (40% glycerol, 0.025% bromophenol, 0.025% xylene
cyanol), the mixtures were directly subjected to 6% PAGE (pH 6.0).
The radioactivity was measured by BAS1000 (Fuji Film) and the data
were analyzed by Muti Gauge Ver. 2.0 (Fuji Film) for the gel mobility
shift assay and the autophosphorylation assay.2.7. Assay of HK inhibitor, I-8-15
Autophosphorylation of CYycG was performed as described previ-
ously [8]. Brieﬂy, 5 pmol of CYycG was mixed with I-8-15 and then
autophosphorylated with [c-32P]ATP for 5 min at room temperature
in 10 ll of reaction buﬀer A [50 mM Tris–HCl (pH 7.5), 50 mM
KCl, 50 mM MgCl2] containing 2.5 lM ATP. To stop the reaction,
a 2· sample buﬀer [120 mM Tris–HCl (pH 6.8), 20% glycerol, 4%
SDS, 10% b-mercaptoethanol, 0.1% BPB] was added. After SDS–
PAGE, IC50 was determined as described previously [8].
2.8. Antibacterial susceptibility
Antibacterial susceptibility testing was done by the broth microdilu-
tion method following the guidelines of the National Committee for
Clinical Laboratory Standards (NCCLS).
2.9. Synthesis of I-8-15 (1-dodecyl-2-isopropylimidazole)
2-Isopropylimidazole (1.44 g, 13.1 mmol) in 10 ml of chloroform
was stirred at 70 C and then dodecyl bromide (1.17 g, 4.69 mmol)
was added dropwise to the solution and stirred for 1 day at the same
temperature. The solution was evaporated to remove chloroform un-
der pressure, and the residue was subjected to column chromatography
on silica gel using the methanol and chloroform at a ratio of 1:15 (v/v)
to aﬀord 1-dodecyl-2-isopropylimidazole in 97.6% yield (1.30 g). The
structure of the compound I-8-15 was identiﬁed as 1-dodecyl-2-isopro-
pylimidazole using 1H NMR and high-resolution mass spectroscopy.3. Results and discussion
3.1. Construction of a vector for targeting protein
homodimerization
From the results of the crystal structure analysis of the Ther-
motoga maritime IclR protein (TM IclR) [22], it was predicted
that this protein is composed of two domains: the N-terminal
Fig. 3. Homodimerization of N100-zip. (A) Chemical cross-linking of
N100-zip. IclR (lanes 1 and 2), N100 (lanes 3 and 4) or N100-zip (lanes
5 and 6) was incubated in the presence (lanes 1, 3 and 5) or absence
(lanes 2, 4 and 6) of DSS. They were then analyzed by SDS–PAGE
followed by Western blot with polyclonal antibody against IclR.
Bottom and top of the black arrow show monomer and dimer of IclR.
Bottom, middle and top of the white arrow show monomer, dimer and
trimer of N100-zip, respectively. (B) Gel mobility shift assay. The
labeled probe as described in Section 2 was incubated with the puriﬁed
proteins, IclR (lanes 1–4), N100 (lanes 5–8), N100-zip (lanes 9–12)
(lanes 1, 5 and 9: 0 pmol; lanes 2, 6 and 10: 0.1 pmol; lanes 3, 7 and 11:
0.2 pmol; lanes 4, 8 and 12: 0.4 pmol) and BSA (lane 13: 150 pmol) for
10 min at 37 C in the binding buﬀer. The arrow shows the shift band
of the DNA protein complex.
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motif and a regulatory domain in the C-terminal of the pro-
tein, which is involved in its binding to a signal molecule.
These two domains are linked by an a helix (H4) [22]. The
binding of a signal molecule to the C-terminal domain of IclR
is presumed to repress the transcription of target genes by
modulating either DNA binding activity or multimerization
of IclR [22]. Database homology searches have identiﬁed many
IclR-like proteins, known as the IclR family, which shows a
conserved C-terminal region. E. coli IclR also forms a dimer
and regulates both the aceBAK operon and its own expression
[23–25]. To localize the essential domain for the IclR dimeriza-
tion, we constructed four plasmids, pFI001, pFI002, pFI003
and pFI004, that contained a series of deletions of the E. coli
IclR gene (Fig. 2). Each plasmid expresses a diﬀerent length
of IclR repressor and is, therefore, expected to diﬀer in its abil-
ity to form a dimer [23,24] and in its binding activity to the iclR
promoter sequence (Fig. 2). In order to quantify the dimeriza-
tion ability of chimeric proteins as ﬂuorescent intensity, the
EGFP gene was fused directly downstream to the iclR pro-
moter. In E. coli JM109 containing pFI001 (JM109/pFI001)
expressing the full length (274 a.a.) of the iclR gene, EGFP
expression (ﬂuorescent intensity, 21 289 counts) was almost
completely repressed in comparison with that of JM109/
pF001 (733 941 counts). On the other hand, the ﬂuorescent
intensity of JM109/pFI003, JM109/pFI002 and JM109/
pFI004 showed approximately 18-, 17- and 6-fold increases
(Fig. 2B, lanes 2–4), respectively, compared to that of
JM109/pFI001 (Fig. 2B, lane 1). These results suggest that a
key region controlling the repressor activity of IclR resides be-
tween 274 and 100 a.a. residues from the N-terminal amino
acid of IclR. It should be noted that the region between 117
and 100 a.a. corresponds to the a helix (H5) of TM IclR [22].
The results of Fig. 2B are consistent with the current model
[7] in which the C-terminal domain of IclR modulates multi-
merization of IclR for DNA binding. To conﬁrm the role of
the C-terminal domain of IclR, a chimeric repressor plasmid
(pFI006) (Fig. 2A, lane 6), in which the leucine zipper of yeast
GCN4 [18,19] was fused to the N-terminal (100 a.a.) portion of
IclR (N100-zip), was constructed and expressed in JM109. Our
results from the reporter assay revealed that the chimeric mol-
ecule (N100-zip) eﬀectively repressed the expression of EGFP
(Fig. 2B, lane 6), while the repressor activity was signiﬁcantly
reduced in JM109/pFI007 (Fig. 2B, lane 5), where the DNA
binding domain (NcI; residue 2-132) of the kcI repressor [16]
was fused to N100. These results suggest that the above-iden-
tiﬁed domain (274–100 a.a.) of IclR (Fig. 2A, lanes 2 and 3) is
essential for dimerization as well as DNA binding activity. To
further conﬁrm these results, we conducted cross-linking and
gel shift analyses. Consequently, the dimer of IclR (full length)
was observed in the presence of DSS (Fig. 3A, lanes 1 and 2).
On the other hand, the N100 form of IclR did not react with
polyclonal antibody against IclR (Fig. 3A, lanes 3 and 4),
but the N100-zip formed a dimer and reacted with its antibody
(Fig. 3A, lanes 5 and 6). To test whether IclR and N100-zip di-
rectly interact with the promoter region containing the iclR
box, we carried out gel mobility shift assays (Fig. 3B). As a re-
sult, a marked shift was observed when IclR protein (0.1–
0.4 pmol) was used (Fig. 3B, lanes 1–4). However, no shift
bands appeared by the addition of the N100 fragment of IclR
(0.1–0.4 pmol) (Fig. 3B, lanes 5–8) or BSA (150 pmol) (Fig.
3B, lane 13). In contrast, a signiﬁcant gel shift was observedat a high concentration of N100-zip (0.1–0.4 pmol) (Fig. 3B,
lanes 9–12). Therefore, the chimeric molecule consisting of
the N100 of E. coli IclR and the leucine zipper of yeast
GCN4 is indeed capable of forming a dimer and functionally
repressing the iclR promoter.
To further validate our results, we constructed a chimeric
gene using the homodimerized C-terminal domain (CFad; res-
idues 83-240) of the FadR of E. coli [20], which contains a
homodimerization domain (HD). We found that the chimeric
repressor of N100 and CFadR is capable of suppressing a pro-
moter such as N100-zip (Fig. 2B, lanes 6 and 7). These results
conﬁrm our notion that the region between 274 and 100 a.a. of
IclR is involved in dimerization and that this region can be re-
placed with other functional homodimerization domains
(Fig. 4).
3.2. A novel drug discovery system
To clarify the homodimerization domain of YycG, N100
was fused to YycG cytoplasmic domain (CYycG) to construct
pFI028 (Fig. 2A). As shown in Fig. 2B lane 8, JM109/pFI028
showed a substantial decrease (up to 3-fold) of ﬂuorescent
activity compared to that of N100 (Fig. 2B, lane 3). This result
strongly suggests that the cytoplasmic region of YycG is in-
deed involved in the homodimerization of the N100-CYycG
chimera, which modulates the DNA binding activity for
repressing EGFP gene expression (Fig. 4).
Fig. 4. Schematic diagram of homodimerization system.
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localizes the dimerization domain of virtually any protein that
is capable of forming a homodimer. Therefore, the system is
potentially useful for screening inhibitors of such dimerization.
To test this possibility and to identify YycG inhibitors, we
screened a chemical library against JM109/pFI028 and
JM109/pFI001 in 96-titer wells (Fig. 5A). Through this screen-
ing process, we identiﬁed a compound named I-8-15, which
signiﬁcantly increased ﬂuorescent intensity of JM109/pFI028,
while no change in ﬂuorescent intensity was observed
in JM109/pFI001 in the presence or absence of I-8-15
(Fig. 5A). To conﬁrm that I-8-15 indeed inhibits CYycGFig. 5. Isolation of I-8-15. (A) Speciﬁc interference of I-8-15 against
CYycG. E. coli JM109/pFI028 () or pFI001 (m) was cultured in the
presence of I-8-15, and ﬂuorescence was measured as described in
Section 2. (B, C) The eﬀect of other HK inhibitors, Aranorosinol B and
NH0891, against CYycG. E. coli JM109/pFI028 or pFI001 was
cultured in the presence of Aranorosinol B or NH0891, and ﬂuores-
cence was measured as described in Section 2.dimerization, we performed a cross-linking experiment using
N100-CYycG (Fig. 6, lanes 1 and 2). As a result, the dimer
band of N100-CYycG was observed in the presence of DSS
(Fig. 6, lane 2) but not in the absence of DSS (Fig. 6, lane
1). This result indicates that N100-CYycG in fact formed a di-
mer. Next, we investigated the eﬀect of I-8-15 on the dimeriza-
tion of N100-CYycG (Fig. 6, lanes 3 and 4). The dimer band of
N100-CYycG remained in the presence of DSS and DMSO
(Fig. 6, lane 3) but no band was observed in the presence of
DSS and I-8-15 (Fig. 6, lane 4). On the other hand, the dimer
band of N100-zip was observed even in the presence of DSS
and I-8-15 (Fig. 6, lane 5). These results suggest that I-8-15
speciﬁcally inhibits the CYycG of S. aureus, thus, causing
the conformational change and inhibiting the dimerization.
Next, we investigated the DNA binding ability of N100-
CYycG for the IclR promoter in the presence of I-8-15 (50–
200 lg/ml), but no inhibitory eﬀect on the gel shift assay was
observed (data not shown). Even though JM109/pFI028
(N100-CYycG) was incubated in the presence of I-8-15 (Fig.
5A), the ﬂuorescent intensity increased only twice more than
in the absence of I-8-15. Thus, we presumed that I-8-15 actsFig. 6. Mode of action of I-8-15 against CYycG. After N100-CYycG
(lanes 1–4) or N100-zip (lane 5) was incubated in the presence of
DMSO (lane 3) or I-8-15 (lanes 4 and 5: 1000 lg/ml), DSS was added
for chemical cross-linking reaction (lanes 2–5). These were then
analyzed by SDS–PAGE followed by Western blot with polyclonal
antibody against IclR. Bottom and top of the black arrow
show monomer and dimer of N100-CYycG. Bottom, middle and top







E. coli JM109 >200
B. sabtilis 168 25
MRSAa 25
VREb 50
Mol. Wt, molecular weight; IC50, 50% inhibitory concentration of I-8-
15 against in vitro CYycG autophosphorylation activity.
aMethicillin-resistant S. aureus 870307 isolated clinically.
bVancomycine-resistant Enterococcus faecalis NCTC 12201 [27].
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that I-8-15 indeed inhibits the activity of CYycG, in vitro auto-
phosphorylation of CYycG was examined. I-8-15 inhibited
autophosphorylation of CYycG with an IC50 of 76.5 lM (Ta-
ble 1). Importantly, I-8-15 also signiﬁcantly inhibited the
growth of MRSA and VRE with MICs at 25 and 50 lg/ml,
respectively (Table 1). We also tested two other HK inhibitors,
Aranorosinol B [8] and NH0891 [26], that had previously been
reported to inhibit CYycG at IC50 of 211 and 750 lM, respec-
tively. However, when these compounds were added in the cul-
ture of JM109/pFI028 at a concentration of 100 lg/ml, no
increase in ﬂuorescent intensity was observed (Fig. 5B and
C). These results suggest that I-8-15 acts on CYycG in a com-
pletely diﬀerent manner from that of Aranorosinol B and
NH0891 and exerts its bactericidal activity by inhibiting the
autophosphorylation of CYycG.
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